文献速递生殖医学

预测复发性妊娠丢失患者后续妊娠丢失的列线图与风险分层

A nomogram and risk stratification to predict subsequent pregnancy loss in patients with recurrent pregnancy loss.
PubMed 文献 · Hum Reprod · 2024-01-01

本研究基于上海交通大学医学院附属仁济医院生殖免疫门诊2020年1月1日至2022年12月31日的3387例复发性妊娠丢失(RPL)患者,纳入符合标准的1153例进行回顾性分析。通过多因素logistic回归构建列线图预测后续妊娠丢失,训练队列AUC为0.808(95%CI:0.770-0.846),验证队列AUC为0.731(95%CI:0.660-0.802),并据风险评分将患者分为低危和高危亚组,两组妊娠丢失率差异有统计学意义(P<0.001)。

要点

  • 列线图纳入年龄、既往妊娠丢失次数、狼疮抗凝物、抗心磷脂IgM、抗磷脂酰丝氨酸/凝血酶原复合物IgM、抗双链DNA抗体、花生四烯酸诱导的血小板聚集、凝血酶时间及双侧子宫动脉收缩/舒张比值之和。
  • 列线图预测后续妊娠丢失的AUC在训练队列为0.808(95%CI:0.770-0.846),验证队列为0.731(95%CI:0.660-0.802)。
  • 低危组与高危组妊娠丢失率差异有统计学意义(P<0.001)。

核心结论

  • 基于多因素logistic回归识别的独立危险因素构建的列线图,可作为预测RPL患者后续妊娠丢失可能性的可靠工具。
  • 列线图预测效能优于仅纳入年龄和既往妊娠丢失次数的模型。
  • 研究已将列线图整合至在线网页工具以供临床应用。

研究设计与样本

  • 回顾性研究,纳入2020年1月1日至2022年12月31日在上海交通大学医学院附属仁济医院生殖免疫门诊初次就诊的3387例RPL患者,其中1153例符合纳入标准并纳入分析。
  • RPL定义为同一伴侣在妊娠28周前发生两次或以上妊娠丢失(包括生化妊娠丢失)。
  • 数据通过初始问卷、妊娠后每两周访视、病历调取及失访患者电话随访收集,涵盖基本人口学、实验室指标(自身抗体、外周免疫凝血及内分泌因素)、子宫及子宫内膜超声结果和后续妊娠结局。
  • 采用R软件清洗数据,按妊娠成功与妊娠丢失以7:3比例分为训练队列(n=808)和验证队列(n=345)。
  • 通过多因素logistic回归识别独立预测因子,构建列线图,采用10折交叉验证评估,并与仅纳入年龄和既往妊娠丢失次数的模型比较;使用AUC、校准曲线、决策曲线分析(DCA)和临床影响曲线分析(CICA)评价列线图。

主要发现

  • 列线图纳入年龄、既往妊娠丢失次数、狼疮抗凝物、抗心磷脂IgM、抗磷脂酰丝氨酸/凝血酶原复合物IgM、抗双链DNA抗体、花生四烯酸诱导的血小板聚集、凝血酶时间及双侧子宫动脉收缩/舒张比值之和。
  • 列线图AUC在训练队列为0.808(95%CI:0.770-0.846),在验证队列为0.731(95%CI:0.660-0.802)。
  • 10折交叉验证AUC范围为0.714至0.925,平均AUC为0.795(95%CI:0.750-0.839)。
  • 列线图AUC优于仅纳入年龄和既往妊娠丢失次数的模型。
  • 校准曲线、DCA和CICA显示良好一致性和临床适用性;低危组与高危组妊娠丢失率差异有统计学意义(P<0.001)。

临床怎么用

  • 作者将列线图整合至在线网页工具,供临床应用于RPL患者后续妊娠丢失的风险预测与分层。

局限性

  • 本研究为回顾性研究,且仅关注来自单一生殖免疫门诊的患者,缺乏外部验证数据。
  • 胚胎染色体异常对妊娠丢失的潜在影响无法排除。
  • 所有病例均接受药物治疗,影响了妊娠丢失危险因素的探究及模型预测效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Could the risk of subsequent pregnancy loss be predicted based on the risk factors of recurrent pregnancy loss (RPL) patients? SUMMARY ANSWER: A nomogram, constructed from independent risk factors identified through multivariate logistic regression, serves as a reliable tool for predicting the likelihood of subsequent pregnancy loss in RPL patients. WHAT IS KNOWN ALREADY: Approximately 1-3% of fertile couples experience RPL, with over half lacking a clear etiological factor. Assessing the subsequent pregnancy loss rate in RPL patients and identifying high-risk groups for early intervention is essential for pregnancy counseling. Previous prediction models have mainly focused on unexplained RPL, incorporating baseline characteristics such as age and the number of previous pregnancy losses, with limited inclusion of laboratory and ultrasound indicators. STUDY DESIGN, SIZE, DURATION: The retrospective study involved 3387 RPL patients who initially sought treatment at the Reproductive Immunology Clinic of Renji Hospital, Shanghai Jiao Tong University School of Medicine, between 1 January 2020 and 31 December 2022. Of these, 1153 RPL patients met the inclusion criteria and were included in the analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: RPL was defined as two or more pregnancy losses (including biochemical pregnancy loss) with the same partner before 28 weeks of gestation. Data encompassing basic demographics, laboratory indicators (autoantibodies, peripheral immunity coagulation, and endocrine factors), uterine and endometrial ultrasound results, and subsequent pregnancy outcomes were collected from enrolled patients through initial questionnaires, post-pregnancy visits fortnightly, medical data retrieval, and telephone follow-up for lost patients. R software was utilized for data cleaning, dividing the data into a training cohort (n = 808) and a validation cohort (n = 345) in a 7:3 ratio according to pregnancy success and pregnancy loss. Independent predictors were identified through multivariate logistic regression. A nomogram was developed, evaluated by 10-fold cross-validation, and compared with the model incorporating solely age and the number of previous pregnancy losses. The constructed nomogram was evaluated using the AUC, calibration curve, decision curve analysis (DCA), and clinical impact curve analysis (CICA). Patients were then categorized into low- and high-risk subgroups. MAIN RESULTS AND THE ROLE OF CHANCE: We included age, number of previous pregnancy losses, lupus anticoagulant, anticardiolipin IgM, anti-phosphatidylserine/prothrombin complex IgM, anti-double-stranded DNA antibody, arachidonic acid-induced platelet aggregation, thrombin time and the sum of bilateral uterine artery systolic/diastolic ratios in the nomogram. The AUCs of the nomogram were 0.808 (95% CI: 0.770-0.846) in the training cohort and 0.731 (95% CI: 0.660-0.802) in the validation cohort, respectively. The 10-fold cross-validated AUC ranged from 0.714 to 0.925, with a mean AUC of 0.795 (95% CI: 0.750-0.839). The AUC of the nomogram was superior compared to the model incorporating solely age and the number of previous pregnancy losses. Calibration curves, DCAs, and CICAs showed good concordance and clinical applicability. Significant differences in pregnancy loss rates were observed between the low- and high-risk groups (P < 0.001). LIMITATIONS, REASONS FOR CAUTION: This study was retrospective and focused on patients from a single reproductive immunology clinic, lacking external validation data. The potential impact of embryonic chromosomal abnormalities on pregnancy loss could not be excluded, and the administration of medication to all cases impacted the investigation of risk factors for pregnancy loss and the model's predictive efficacy. WIDER IMPLICATIONS OF THE FINDINGS: This study signifies a pioneering effort in developing and validating a risk prediction nomogram for subsequent pregnancy loss in RPL patients to effectively stratify their risk. We have integrated the nomogram into an online web tool for clinical applications. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Natural Science Foundation of China (82071725). All authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Li M, Zhou R, Yu D, et al. A nomogram and risk stratification to predict subsequent pregnancy loss in patients with recurrent pregnancy loss. Hum Reprod. 2024. PMID: 39178353. doi:10.1093/humrep/deae181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。